Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Stability of Cardiac Biomarkers Tested in Different Samples

By LabMedica International staff writers
Posted on 09 Jan 2018
Blood-based biomarkers, such as cardiac troponin (cTn) and galectin-3, are widely used in clinical trials and/or in clinical routines as an aid for the diagnosis and risk stratification of patients with heart disease.

When blood samples are used for biomarker measurements in clinical routine analyses, efforts should be made to process these samples immediately after blood collection to provide immediate results for timely diagnosis and therapy and to avoid any pre-analytical errors.

Doctors at Konventhospital Barmherzige Brueder Linz, (Linz, Austria) tested the hypothesis that the analytes hs-cTnI, hs-cTnT and galectin-3 are stable in vitro at a storage temperature of −80 °C for at least one year, and they used blood samples from clinical routine analyses. The analyte concentrations of 30 patients were measured in heparin-treated plasma, EDTA-treated plasma and serum samples after the following storage conditions: 1) samples used immediately after blood collection for baseline measurements; 2) samples stored for six months at −80 °C after one freeze-thaw cycle; 3) samples stored for one year at −80 °C after two freeze-thaw cycles; and 4) samples stored for one year at −80 °C after one freeze-thaw cycle.

Circulating concentrations of high-sensitivity cardiac troponin I (hs-cTnI) were measured with the STAT High Sensitive Troponin-I assay on the Abbott ARCHITECT i2000SR analyzer. The team measured hs-cTnT concentrations with the Troponin T hs assay on the Roche cobas e 411. The scientists also measured galectin-3 with the Abbott Diagnostics routine Galectin-3 assay on an ARCHITECT i2000SR analyzer.

The investigators reported that baseline hs-cTnI, hs-cTnT and galectin-3 concentrations ranged from 2.3 to 5,436 ng/L, from 5.3 to 850 ng/L, and from 8.3 to 79.3 ng/mL, respectively. After applying the default criterion for analyte stability, the three analytes were stable for at least one year even after two freeze-thaw cycles for each sample type. They observed the following variation in analyte concentrations after storage relative to the baseline values: the interquartile range (IQR) of cardiac troponin results extended from approx. 80% to 115%, and the IQR of galectin-3 results extended from approx. 90% to 110%.

The authors concluded that hs-cTnI, hs-cTnT and galectin-3 were stable under the reported storage conditions irrespective of the sample type used. However, they observed a considerable variation in analyte concentrations after sample storage, which might affect the diagnostic/prognostic value of these analytes in individual patients using frozen blood samples. The study was published in the January 2018 issue of the journal Clinica Chimica Acta.

Related Links:
Konventhospital Barmherzige Brueder


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.